Publications
Peer-reviewed publications and preprints
Broad vaccine protection against globally diverse influenza A H5Nx viruses
Del Rosario JMM, Vishwanath, Frost SDW, Sujit SB, Ashokan, SK, Vendramelli R, Ferrari M, Carnell GW, Vianello L, Pagliari M, Ramzi S, Panzarin VM, Mazzacan E, Fortin A, Vascellari M, Truong T, Tonks P, Ortiz AL, Huang CQ, Einhauser S, Schachtner M, Asbach B, Storisteanu DML, Temperton NL, Davies MN, Moss D, Kinsley R, Wagner R, Kobasa D, Bonfante F, Heeney JL. Cell Reports Medicine 7, 103131, November 17, 2026. DOI: 10.1016/j.xcrm.2026.103131
A digitally immune-optimized influenza vaccine broadly neutralizes swine and human H1N1 influenza viruses and protects from heterologous challenge.
Del Rosario JMM, van Diemen PM, Frost SDW, Vishwanath S, Sujit SB, Ashokan SK, Mollett BC, Ramsay AM, Simpson BS, Asbach B, Huang CQ, Carnell GW, Chan A, Tonks P, Temperton NJ, Davies MN, McCauley JW, Kinsley R, Wagner R, Everett HE, Heeney JL. J Virol. 2026 Oct 6:e0107326. DOI: 10.1128/jvi.01073-26
A computational method to design broad-spectrum T cell-inducing vaccines applied to Betacoronaviruses.
Palmer P, Fedosyuk S, Parthasarathy S, Holbrook J, George C, O’Reilly L, Wiegand L, Carnell GW, Heeney JL, Vishwanath S. Cell Rep Methods. 2026 Jun 29:101508. DOI: 10.1016/j.crmeth.2026.101508
A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
Munro AP, Ferrari M, Kinsley R, Egan D, Vishwanath S, Bower T, Chan A, Davies M, Rosario JMMD, Moss R, Enever Y, Asbach B, Wagner R, Bousfield R, Chatterjee K, Cornelius V, Faust SN, Heeney JL. J Infect. 2026 Jun;92(6):106759. DOI: 10.1016/j.jinf.2026.106759
Genomic epidemiology and evolutionary analysis of Lassa virus from small mammals suggest bidirectional viral movement across humans and animals.
Happi AN, Ogunsanya OA, Sijuwola AE, Saibu FM, Akano K, Ayinla AO, Daodu RO, Page B, Olumade TJ, Oguzie JU, Oluniyi PE, Adedokun OA, Fadele J, Nwofoke C, Elias OT, Ogundana KE, Lawal OZ, Nosamiefan I, Okolie J, Adelabu A, Lombardi K, Eller LA, Broach E, Prins PA, Heeney JL, Modjarrad K, Njatou TLFA, Parker ZF, McCauley M, Vasan S, Parker E, Collins ND, Michael NL, Happi CT. Virus Evol. 2026 Jun 1;12(1):veag032. DOI: 10.1093/ve/veag032
Computationally designed haemagglutinin with nanocage plug-and-display elicits pan-H5 influenza vaccine responses.
Huang CQ, Hills RA, Carnell GW, Vishwanath S, Aguinam ET, Chan ACY, Palmer P, O’Reilly L, Tonks P, Temperton N, Frost SDW, Tiley LS, Howarth MR, Heeney JL. Emerg Microbes Infect. 2025 Jun 6:2511132. DOI: 10.1080/22221751.2025.2511132
Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine.
Pfranger M, Krause N, Asbach B, Meier J, Carnell G, Scheer L, Kalender A, Brenner D, Tonks P, Frost S, Wright E, Jordan I, Kennedy E, Hewson R, Blacklaws B, Chan A, Parthasarathy S, Dowall S, Carroll M, Sandig V, Fedosyuk S, Kinsley R, Heeney J, Wagner R. J Gen Virol. 2025 Oct;106(10):002157. DOI: 10.1099/jgv.0.002157
Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD.
Olivier J, George C, Huang CQ, Sujit SB, Tonks P, Cantoni D, Grove J, O’Reilly L, Geiger J, Dohmen C, Mummert V, Samuel AR, Plank C, Kinsley R, Temperton N, Pfranger M, Wagner R, Heeney JL, Vishwanath S, Carnell GW. Emerg Microbes Infect. 2025 Dec;14(1):2502011. DOI: 10.1080/22221751.2025.2502011
Immune imprinting and next-generation coronavirus vaccines.
Huang, C.Q., Vishwanath, S., Carnell, G.W. et al. Nat Microbiol 8, 1971–1985 (2023). DOI: 10.1038/s41564-023-01505-9
Simultaneous broad protection against Ebola Sudan, Marburg and Lassa viruses conferred by a DNA primed MVA-vectored multivalent vaccine
Kobasa D, Pfranger M, Krause N, Fedosyuk S, Wiegand L, Jordan I, Sandig V, Leupold C, Asbach B, Storisteanu D, Kalender A, Scheer L, Brenner D, Prévost J, Tailor N, Vendramelli R, Warner B, Truong T, Parthasarathy S, Holbrook J, Carnell G, Chan A, Whittaker C, Ugwu C, Happi C, Frost S, Kinsley R, Safronetz D, Wagner R, Heeney JL.
Efficacy and potential human and economic impact of a broadly protective betacoronavirus vaccine
Carnell G, Vendramelli R, Whittaker C, Holbrook J, Parthasarathy S, Stewart H, Olivier J, Warner B, Truong T, George C, Sujit S, Ashokan S, Suau Sans M, Huang C, Wells D, Tonks P, Pfranger M, Einhauser S, Neckermann P, Cantoni D, Chan A, O’Reilly L, Ohlendorf L, Unwins I, Rautenbach S, Ferrari M, Firth A, Geiger J, Dohmen C, Mummert V, Samuel A, Plank C, Del Rosario J, Temperton N, Asbach B, Frost S, Kinsley R, Vishwanath S, Fedosyuk S, Wagner R, Kobasa D, Heeney JL.
Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.
Vishwanath, S., Carnell, G. W., Billmeier, M., Ohlendorf, L., Neckermann, P., Asbach, B., … & Heeney, J. L. (2024). npj Vaccines, 9(1), 164.
Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature.
Cantoni, D., Wilkie, C., Bentley, E. M., Mayora-Neto, M., Wright, E., Scott, S., … & Temperton, N. J. (2023). Frontiers in Immunology, 14, 1184362.
A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses.
Vishwanath, S., Carnell, G. W., Ferrari, M., Asbach, B., Billmeier, M., George, C., … & Heeney, J. L. (2023). Nature Biomedical Engineering, 1-14.
Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.
Carnell, G. W., Billmeier, M., Vishwanath, S., Suau Sans, M., Wein, H., George, C. L., … & Heeney, J. L. (2023). Frontiers in Immunology, 14, 1118523.
Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) neuraminidase pseudotypes as tools for pandemic preparedness and improved influenza vaccine design
da Costa, K. A., Del Rosario, J. M. M., Ferrari, M., Vishwanath, S., Asbach, B., Kinsley, R., … & Temperton, N. J. (2022). Vaccines, 10(9), 1520.
Human seasonal coronavirus neutralization and COVID‐19 severity.
Wells, D. A., Cantoni, D., Mayora‐Neto, M., Genova, C. D., Sampson, A., Ferrari, M., … & Heeney, J. L. (2022). Journal of medical virology, 94(10), 4820-4829.
Gene delivery of a single, structurally engineered Coronavirus vaccine antigen elicits SARS-CoV-2 Omicron and pan-Sarbecovirus neutralisation [Preprint].
Heeney, J., Vishwanath, S., Carnell, G., Ferrari, M., Asbach, B., Billmeier, M., … & Frost, S. (2022). Research Square.
Exploiting pan influenza A and pan influenza B Pseudotype libraries for efficient vaccine antigen selection.
Del Rosario, J. M. M., Da Costa, K. A., Asbach, B., Ferrara, F., Ferrari, M., Wells, D. A., … & Temperton, N. J. (2021). Vaccines, 9(7), 741.
Latest News
August 2026
DIOSynVax brings together genomics, synthetic biology, artificial intelligence (AI), and immunology to design broadly protective vaccine antigens that are compatible with most vaccine delivery systems.
August 2026
The first human clinical trial of a universal Sarbeco coronavirus vaccine has shown that the vaccine is safe and has no significant side-effects.
July 2026
The AI Discovery Awards are a core part of Nebius’ commitment to supporting startups develop AI apps in healthcare and life sciences.
June 2026
New vaccine technology created with the help of AI could provide immunity against whole families of viruses and protect from any future mutations.
June 2026
AI has been used to develop a “fundamentally new” type of vaccine that could protect against large swathes of viruses and prevent pandemics.
May 2026
Researchers warn funding cuts have left the country vulnerable to the deadly virus and say a vaccine is potentially just months away.
June 2025
Our Next-Generation Influenza vaccines have now demonstrated efficacy and safety in animal models and are ready for human trials.
April 2025
This bilateral project is supported by Innovate UK and Enterprise Singapore, as part of the UK-Singapore Collaborative R&D Call.
March 2025
This innovative technology aims to protect against a wide array of influenza strains.
January 2025
Driving the clinical development of its NextGen Influenza Vaccines invluding Bird-Flu.
October 2024
Insights from DIOSynVax CSO Jonathan Heeney at the World Vaccine Congress.
October 2024
We are thrilled to announce the appointment of Ron Moss as our new Chief Executive Officer.
March 2024
ProBioGen proudly announces a partnership with DIOSynVax Ltd to manufacture DIOS-HFVac3.
September 2023
Cambridge scientists hopeful that jab could also protect against future diseases.
September 2023
Studies show that just one antigen can be modified to provide a broadly protective immune response in animals.
April 2023
The vaccine has been developed by Professor Jonathan Heeney at the University of Cambridge and spin-out company DIOSynVax.
June 2022
Ambitious research project already underway aims to stamp out such viruses entirely.
April 2022
Cambridge start-up searches for next Covid jab in animal faeces.
March 2022
The Coalition for Epidemic Preparedness Innovations has pledged up to $42m to support.
March 2022
WHO consultation on COVID vaccines research: Why do we need a pan-sarbecovirus vaccine?
March 2022
The Secretary of State for Health and Social Care spoke at the summit on Tuesday 8 March 2022.
March 2022
A UK-made vaccine to protect people against future pandemics has received global backing.
February 2022
Covid vaccines: the race for a single shot to prevent new pandemics.
December 2021
A trial has begun of a new needle-free Covid-19 vaccine to protect against variants of the virus.
August 2021
COVID: we spoke to experts designing a single vaccine to defeat them all.
February 2021
A coronavirus vaccine being developed will aim to “take care of” future variants of the virus.